Cordis Corporation, through its subsidiaries, develops and manufactures stents, catheters, and guidewires for interventional medicine, minimally invasive computer-based imaging, and electrophysiology. The company offers cardiology products, which include transradial products; diagnostic products, such as access kits, sheath introducers, diagnostic guidewires, and diagnostic catheters; access products, which include guiding catheters; steerable guidewires; and interventional products, including PTCA dilatation, PTCA dilatation, and NC RX PTCA dilatation catheters. It also provides endovascular products, such as lower extremity solutions, which include CTO catheters, re-entry catheters, hydrophilic nitinol guidewires, hydrophilic-coated diagnostic catheters, PTA dilatation catheters OTW PTA dilatation catheters, PTA dilatation catheters, iliac stent systems, and dilatation catheters; carotid stent systems, including carotid stent systems and RX emboli capture guidewire systems; vena cava filters, such as permanent vena cava filters and retrievable vena cava filters; and vascular closure devices. In addition, the company offers nitinol self-expandable stent systems for treating patients with obstructive superficial femoral artery disease; biliary products, such as transhepatic biliary stents; and expert services and educational resources for physicians and other healthcare professionals. It serves healthcare professionals and patients worldwide. The company was founded in 1959 and is headquartered in Bridgewater, New Jersey. As of February 22, 1996, Cordis Corporation operates as a subsidiary of Johnson & Johnson.